Skip to main content

Talk Bio

Search This Blog

Five of the biggest venture capital raises of Q3 2026

on October 07, 2026

Get link
Facebook
X
Pinterest
Email
Other Apps

The five largest Q3 2026 venture raises identified in the available round-by-round data were:
Databricks — $5 billion; Crusoe — $3.9 billion; The Boring Company — $3 billion; Cognition — $2 billion; and Joulent — $1.75 billion.

Databricks’ $5 billion strategic growth round was the quarter’s largest listed round. Another Q3 market roundup also names Safe Superintelligence at $5 billion, tied for the top spot, so the top five may vary depending on which deals are included in a tracker.

The biggest rounds were heavily concentrated in AI and infrastructure:
Databricks, Crusoe, and Cognition are AI-related, while The Boring Company develops transportation infrastructure.

Sources:

Q3 2026 Posted A Record Count Of Billion-Dollar Rounds ...

5 biggest venture capital raises of Q3 2026

North America's Startup Funding Falls In Q3 As AI Giants ...

hellomarvisaitoday.com · articles · 2d9a2cda-6708-427 companies raise billion-dollar rounds in Q3 2026

Global Startup Funding in Q3 2026: AI Mega-Rounds and What ...

Crunchbase Q3 2026 funding: $159B, 27 billion-dollar rounds ...

Q3 2026 Venture Funding: $159B, AI at 64%, 27 Mega-Rounds

VC funds raised in Q3 2026 to invest in European startups - Vestbee

Global Venture Funding Jumps 122% In August As Streak ...

Q3 2026 Venture Funding: $69.0B Across 337 Tracked ...

AI News, Oct 6: AI Took 64% of All Venture Capital

Crunchbase: Q3 Venture Hit $159B, AI Took 64%

AI Agent Startup Funding: August and September 2026 (Q3 Tracker)

www.secondtalent.com · resources · ai-startup-funding-investmentAI Startup Funding and Investment Statistics (Sep, 2026)

news.crunchbase.com · sections · ventureVenture Archives - Crunchbase News

Boring Company cognition/ Crusoe Databricks Joulent SAFE-Biopharma Standard Superintelligence venture capital

Get link
Facebook
X
Pinterest
Email
Other Apps

Popular Posts

Anthropic Acquires Stealth AI Biotech Startup Coefficient Bio in $400M Stock Deal

Anthropic acquired stealth biotech AI startup Coefficient Bio in an all-stock deal valued at approximately $400 million. The deal was reported by The Information and confirmed by sources to TechCrunch, Fierce Biotech, and others; it has closed. Coefficient Bio, founded in 2025 (about 8 months ago), focused on using AI to enhance drug discovery, biological research, R&D planning, and regulatory strategy. Key founders include Nathan C. Frey, Samuel Stanton (ex-Genentech Prescient Design), Aris Theologis (CEO, ex-Evozyne), and Joyce Hong. The small team (6-10 people), backed by Dimension VC, will join Anthropic's health and life sciences team led by Eric Kauderer-Abrams. This acquisition supports Anthropic's expansion into healthcare, following launches like Claude for Life Sciences (October 2025) and Claude for Healthcare (January 2026). Sources:

Biotech reverse-merger wave grows as Marea and North Immunology secure $405 million

The biotech reverse-merger trend continued with two deals announced September 17, 2026: North Immunology’s merger with Aethlon Medical and Marea’s merger with Lisata Therapeutics. North Immunology will merge with Nasdaq-listed Aethlon Medical and raise approximately $180 million through a private placement. The combined company will retain the North Immunology name and is expected to trade under ticker NRTX. North plans to use the financing to advance NOR-101, a dual-targeting IL-13/IL-18 antibody for atopic dermatitis, into clinical testing. The cash is expected to fund operations into the second half of 2028. North Immunology investors are expected to own about 95.25% of the combined company, while existing Aethlon shareholders will hold about 4.75% and receive contingent rights tied to Aethlon’s legacy Hemopurifier business. Closing is expected in the first quarter of 2027, subject to approvals. Marea’s stock-for-stock combination with Lisata includes a $225 million privat...

BMS ends Orum’s $100M AML degrader-antibody conjugate program after Phase 1 review

Bristol Myers Squibb has discontinued BMS-986497, formerly Orum Therapeutics’ ORM-6151, after reviewing early Phase 1 clinical data. Neither company publicly detailed the data or the precise reason for the decision. The program was a CD33-directed degrader-antibody conjugate intended for acute myeloid leukemia and high-risk myelodysplastic syndromes. It used an antibody to deliver a GSPT1 protein-degrader payload to CD33-expressing malignant cells. BMS acquired the asset in 2023 for $100 million upfront, with up to $80 million in additional development milestones. Orum keeps the upfront payment, but the remaining milestone opportunity has been eliminated. The Phase 1 study had evaluated the candidate alone and in combinations involving azacitidine and venetoclax across sites in the U.S., Europe and Canada. Because the transaction was structured as an asset purchase rather than a license, reporting indicates the program does not revert to Orum following BMS’s termination. Sour...

Powered by Blogger

X-Data LLC